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Abstract
AIM
To investigate the associations of the genetic polymor-
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phisms of vascular endothelial growth factor A (VEGF-A ) 
-1498C>T and -634G>C, with the survival of patients 
with colorectal cancer (CRC). 
METHODS
A prospective cohort consisting of 131 Brazilians 
patients consecutively operated on with a curative 
intention as a result of sporadic colorectal carcinoma 
was studied. DNA was extracted from peripheral 
blood and its amplification and allelic discrimination 
for each genetic polymorphism was performed using 
the technique of polymerase chain reaction (PCR) in 
real-time. The real-time PCR technique was used to 
identify the VEGF-A -1498C>T (rs833031) and -634G>C 
(rs2010963) polymorphisms. Genotyping was validated 
for VEGF-A -1498C>T polymorphism in 129 patients and 
for VEGF-A -634G>C polymorphism in 118 patients. The 
analysis of association between categorical variables 
was performed using logistic regression, survival by 
Kaplan-Meier method and multivariate analysis by the 
Cox regression method. 
RESULTS
In the univariate analysis there was a significant 
association (OR = 0.32; P  = 0.048) between genotype 
CC of the VEGF-A  -1498C>T polymorphism and the 
presence of CRC liver metastasis. There was no 
association between VEGF-A  -1498C>T polymorphism 
and VEGF-A -634G>C polymorphism with further clinical 
or anatomopathologic variables. The genotype CC of 
the VEGF-A  -1498C>T polymorphism was significantly 
correlated with the 5-year survival (P  = 0.032), but 
not significant difference (P  = 0.27) was obtained with 
the VEGF-A  -634G>C polymorphism with the 5-year 
survival in the univariate analysis. The genotype CT 
(HR = 2.79) and CC (HR = 4.67) of the polymorphism 
VEGF-A  -1498C>T and the genotype CC (HR = 3.76) 
of the polymorphism VEGF-A  -634C>G acted as an 
independent prognostic factor for the risk of death in 
CRC patients. 
CONCLUSION
The CT and CC genotypes of the VEGF-A  -1498C>T 
and the CC genotype of the VEGF-A -634C>G polymor-
phisms are prognostic factors of survival in Brazilians 
patients with sporadic colorectal carcinoma.
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Core tip: Vascular endothelial growth factor A (VEGF-A) 
affects the tumor biological behavior and phenotype. 
An applied research with relevant achievement that 
will possibly be favored by such information is the 
pharmacogenetics impact of VEGF-A  polymorphisms. 
VEGF-A is a significant goal in the anticancer therapy 
and results about VEGF-A  polymorphisms may enhance 
the targeted therapies. This approach will be of great 
help to the suitability of individual therapies and improve 
the quality of post operative treatment. Moreover, since 
polymorphisms often show a discrepancy between 
ethnic groups, more studies are also warranted to clarify 
the association between the VEGF-A  polymorphisms and 
the CRC in diverse ethnic populations.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common 
malignancies in the world. Despite advances in diagnos­
tic and treatment modalities, patients still face a 
poor prognosis, and a more individualized treatment 
approach appears necessary[1­4]. 
Unlike genetic mutations, polymorphisms represent 
variations of the naturally occurring DNA sequence. 
Polymorphisms are found in at least 1% of the heal­
thy population[5]. The vast majority (90%) of DNA 
polymorphisms is single nucleotide (SNPs)[6,7] and fun­
ctionally neutral. However, certain polymorphisms have 
effects on the regulation of gene expression or on the 
function of the encoded protein[8] and thereby influence 
the susceptibility and severity of the disease[9,10]. Thus, 
the polymorphisms may modify the route of angiogenesis 
and the susceptibility and severity of malignancies[11].
Angiogenesis is a sequence of processes starting with 
vessel dilatation and pericyte recruitment in the pre­
existing vessels, followed by endothelial cell proliferation, 
formation of new vessels and recruitment of perivascular 
cells[9]. In the progress toward malignancy, the normal 
cells must switch to an angiogenic phenotype to attract 
the nourishing vasculature that they depend on for their 
growth[9,11].
Malignant tumors depend on angiogenesis for their 
growth and metastasis[9,11]. It is generally assumed that 
microvessel formation around the tumor is stimulated by 
various angiogenic growth factors secreted by the tumor 
cells[12]. Among them, the vascular endothelial growth 
factor (VEGF), one of the most potent endothelial cell 
mitogens, is considered one of the strongest promoters 
of angiogenesis in CRC[11,12]. The VEGF is vital for the 
invasion and metastasis of neoplasms through the 
formation of new blood vessels from mature endothelial 
cells[13,14]. Moreover, studies have shown that the genetic 
polymorphisms can be used to predict the clinical 
outcomes of gastrointestinal[14,15], breast[16], ovary[17] and 
pancreatic cancer[18].
The cancer targeted therapy with the use of antiangio­
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genic agents is aimed at inhibition of angiogenic function 
and tumor dissemination since neoangiogenesis stimu­
lates the growth and invasion of adjacent tissues by 
tumor cells[9,12]. On the other hand, the inhibition of VEGF 
limits the tumor growth[9,13]. In colorectal carcinoma, 
VEGF levels are increased and they are related to further 
spread and poor prognosis[12,14]. The antiangiogenic 
agent bevacizumab is a humanized monoclonal im­
munoglobulin G antibody against recombinant VEGF 
activity and it is used in the treatment of metastatic 
CRC[13,14]. 
Clinical studies have shown that an association 
between the level of VEGF expression and increased 
microvessel density in tumors is correlated with an 
advanced stage of CRC, and with shorter survival. 
Therefore, it is important to determine the presence 
of metastasis, and patients with CRC and VEGF over­
expression have higher tumor progression and poor 
prognoses[19­21]. Increased VEGF expression in CRC may 
predict the risk of multiple liver metastasis and play a 
role in the spread of CRC cells to the lymph nodes[22]. 
Due to these properties, VEGF has been used as a 
therapeutic target for the creation of anticancer drugs 
and is considered a potential prognostic marker of 
CRC[13,23].
The VEGF-A gene is located on chromosome 6p21.3 
and consists of 8 exons separated by 7 introns that 
exhibit alternative splicing to form a family of proteins[24]. 
This gene is a member of the platelet­derived growth 
factor/VEGF family and encodes a protein that is often 
found as a disulfide-linked homodimer.
The human VEGF-A gene is highly polymorphic, 
with more than 15 SNPs described[24,25], thus enabling 
wide variation in its expression between individuals 
from different ethnic groups, and there are few stu­
dies involving Latinos, Hispanics[20], and particularly 
Brazilians. 
VEGF­A is a dimeric glycoprotein and is considered 
to be the main, dominant inducer of the growth of 
blood vessels. VEGF­A is essential for adults during 
organ remodeling and diseases that involve blood 
vessels in wound healing, tumor angiogenesis, diabetic 
retinopathy and age­related macular degeneration.
The ­634G>C genetic polymorphism in the promoter 
region and the ­1498C>T genetic polymorphism in the 
3’­untranslated region were found to be associated with 
variations in VEGF­A protein synthesis[24,26,27]. Actually, 
the VEGF-A ­634G/C polymorphism appears to be 
associated with a higher VEGF-A expression[28,29]. 
The participation of common genetic polymorphisms 
of VEGF-A in the prognoses of patients with CRC is not 
yet clearly established[19,20,23,25,29]. Furthermore, studies 
investigating the association between VEGF-A genetic 
polymorphisms and CRC risk report conflicting results[30] 
and the specific associations still remain controversial[31]. 
Since VEGF-A is known to be a potent pro­angiogenic 
factor, we evaluated the potential association of 
two VEGF-A genetic polymorphisms (­634G>C and 
­1438C>T) with the clinicopathologic variables and its 
possible implication for prognosis in a population of 
Brazilian patients operated on CRC.
MATERIALS AND METHODS
Study design and sample
The present study was conducted according to the 
ethical principles of the Declaration of Helsinki from the 
World Medical Association and has been approved by 
the Institutional Research Ethics Committees.
The study was conducted as a prospective cohort 
study (observational study) of 131 adult patients of 
both genders with CRC, without a distinction of ethnicity 
and operated on consecutively with a curative intention 
in the period from 2008 to 2011. 
The patients were 80 (61.1%) males and 51 (38.9%) 
females, with a mean age of 58.3 ± 12.5 years (20 
to 85 years) and median age of 58 years. Regarding 
the ethnicity, 121 (92.4%) patients were white and 10 
(7.6%) afrodescendants.
The following patients were excluded from the study: 
Those with familial adenomatous polyposis, colorectal 
neoplasia other than carcinoma, inflammatory bowel 
disease, other hereditary CRC syndromes, submitted 
to neoadjuvant treatment or with synchronous/meta­
chronous tumors elsewhere, except for basal cell car­
cinoma of skin, and those who were impossible to con­
tact, whether the patients or the patient’s relatives, to 
obtain the necessary information. 
Collection and processing of biological material
Peripheral blood samples were collected by venipuncture 
into tubes containing 0.1% EDTA and kept in the 
refrigerator at 4 ℃ for up to 48 h. If DNA extraction 
did not take place within this period, the samples were 
frozen for a maximum of seven days at a temperature 
of ­20 ℃. DNA extraction was performed using the 
method of salting out and storing the material in a 
freezer at ­80 ℃.
Surgery data
Regarding the anatomical distribution of the tumors, 
98 (74.8%) was found in the colon: 41 (31.3 %) in the 
right colon, 7 (5.3%) in transverse and 50 (38.2%) in 
the left colon. In the remaining 33 (25.2%) patients, the 
tumors were located in the rectum. A right colectomy 
was performed in 42 (32.1%) cases, a left colectomy in 
45 (34.3%), rectosigmoidectomy in 41 (31.3%) and an 
abdominoperineal resection in 3 (2.3%). 
Genotyping
The real­time PCR technique was used to identify 
genetic polymorphisms in VEGF-A (rs833061 and 
rs2010963) genes. DNA was amplified using Taqman 
assays C_10 (rs833061) and C_10 (rs2010963 (Applied 
Biosystems, Life Technologies Corporation, Foster City, 
CA, United States) and VIC/FAM dyes (FAM™/ROX™ 
and VIC®/ROX™ Dye Normalization Plates, Applied Bio­
systems, Life Technologies Corporation, Foster City, CA, 
Espírito Santo GF et al . VEGF polymorphisms in colorectal cancer patients
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United States). The dye was used as ROX™ passive 
reference. In each PCR reaction, the following were 
used: 10 µL of TaqMan Universal Master Mix II (Applied 
Biosystems, Life Technologies Corporation, Foster City, 
CA, United States), 1.0 µL of TaqMan Pre­Designed SNP 
Genotyping Assays 20 × solution (Applied Biosystems, 
Life Technologies Corporation, Foster City, CA, United 
States), 30-50 ng of genomic DNA and a final volume of 
20 µL of Nuclease­Free Water (Promega, Madison, WI, 
United States). The equipment used for amplification 
and allelic discrimination was the Fast ABI­7500 (Applied 
Biosystems, Life Technologies Corporation, Foster City, 
CA, United States). Protocols for genotyping were 
performed according to the manufacturer involving 
the cycling amplification for 10 min at 95 ℃ and then 
40 cycles for 15 s at 92 ℃ and for 1 min at 60 ℃. 
At that time, there was the post­run for 1 min allele 
determination. Negative controls (no template control –
NTC) were used, results were analyzed and 10% of all 
samples were genotyped more than once to ensure there 
was no contamination. Genotyping was validated for 
VEGF-A ­1498C>T polymorphism in 129 patients and 
for VEGF-A ­634G>C polymorphism in 118 patients.
Statistical analysis
The estimation of the sample power, calculated as the 
ability to detect a hazard ratio (HR) ≥ 1.7 with an alpha 
value of 0.05 and a statistical power of 80% provided a 
minimum sample size of 112 individuals. The estimation 
was performed using the Stata 11.0 (Stata Statistical 
Software, StataCorp LP, College Station, TX, United 
States).
The variable survival was well­defined as the time 
elapsed between the date of the surgery and the event 
of interest represented by the patient’s death by CRC. 
Operationally, this variable is composed of the duration 
of the follow­up after the operation that was previously 
established with a maximum duration of 60 mo or the 
occurrence of death. The clinical variables analyzed were 
gender, age and presence of metastasis and/or relapse 
after the operation. 
The analyzed histopathological variables were 
the anatomical site of the CRC in the large intestine, 
adjacent invasion, degree of cellular differentiation, 
venous/lymphatic/perineural invasion, and staging of the 
neoplasia according to the 2010 TNM staging system[32].
Patients who survived until the end of the study 
follow­up (60 mo) were considered “censored”. In cases 
in which the event of interest has not occurred after 
exceeding the maximum observation period of the study 
(60 mo), loss of observation or occurrence of death were 
also considered “censored”. 
The univariate analysis was made by means of a log­
rank test. The significant statistical level was considered 
as 5% (P < 0.05).
The Cox regression analysis was used to identify the 
independent effect of the prognostic factors (independent 
variables). For the selection of independent variables to 
be included in the multivariate models of Cox regression, 
each individual variable in the Cox model was tested 
and the following criteria for inclusion in the multivariate 
model were verified: Variables with a descriptive level of 
significance lower than 20% (P < 0.20) in the univariate 
model and the genetic variations (polymorphisms) 
used in this study. For the selection of a final model, 
the automatic selection backwards in Stata 11.0 (Stata 
Statistical Software, StataCorp LP, College Station, TX, 
United States) was used. 
RESULTS
The follow­up period of 131 patients ranged from 1.8 to 
60 mo, with a mean of 33.8 (± 21.9) mo and a median 
of 34.0 mo. Liver metastasis was found in 26 (19.1%) 
patients. The involvement of regional lymph nodes 
occurred in 63 (48.1%) patients and the invasion of 
adjacent organs was found in 26 (19.8%) cases. At the 
end of this follow­up period, 70 (53.4%) patients were 
alive without the disease, 14 (10.7%) were alive with 
the disease, 42 (32.1%) died with CRC, 3 (2.3%) had 
died of causes unrelated to CRC and 2 (1.5%) were lost 
in the follow­up. Thus, censures occurred in 84 (67.9%) 
patients with a complete observation after 60 mo. The 
estimate of overall survival at 5 years was 60.7%, with 
an average of 45.2% (95%CI: 41.5 to 49.0) and a 
median of 33.0%. 
The results of the genotypes’ frequency of the 
VEGF-A ­1498C>T and VEGF-A ­634G>C genetic poly­
morphisms are shown in Table 1. The stages of the CRC 
and their respective polymorphisms of VEGF ­634G>C 
and the VEGF ­1498C>T genes are described in Tables 2 
and 3.
In the univariate analysis there was a significant 
association (OR = 0.32; P = 0.048) between genotype 
CC of the VEGF-A ­1498C>T polymorphism and 
the presence of CRC liver metastasis. There was no 
association between VEGF-A ­1498C>T polymorphism 
with further clinical or anatomopathologic variables 
(Table 4). The VEGF-A ­634G>C polymorphism 
showed no significant association between clinical or 
anatomopathologic variables in the univariate analysis. 
Following the previously established criteria, the 
genotype CC of the VEGF-A ­1498C>T polymorphism 
was significantly correlated with the 5-year survival (P 
  Polimorphism Genotype n  (%)
  VEGF-A -1498C>T (n = 129) CC 27 (20.9)
CT 58 (44.9)
TT 44 (34.1)
  VEGF-A -634G>C (n = 118) CC 26 (22.0)
CG 42 (35.6)
GG 50 (42.4)
Table 1  Frequency of vascular endothelial growth factor 
A -1498C>T and vascular endothelial growth factor A 
-634G>C genetic polymorphisms in blood samples of 
patients with resected colorectal carcinoma
VEGF-A: Vascular endothelial growth factor A.
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= 0.032) (Table 5), but not significant difference (P = 
0.27) was obtained in relation to the VEGF-A ­634G>C 
polymorphism with the 5­year survival in the univariate 
analysis.
In the multivariate analysis, the genotypes CT (HR = 
2.79; 95%CI: 1.01­7.66) and CC (HR = 4.67; 95%CI: 
1.51­14.43) of VEGF-A ­1498C/T polymorphism and 
the genotype CC (HR = 3.76; 95%CI: 1.29­10.93) 
of VEGF-A ­634C>G polymorphism were associated 
with a reduced 5­year survival (Table 6; Figures 1 and 
2). The VEGF-A ­1498C/T and the VEGF-A ­634G>C 
polymorphisms showed no significant association 
between clinical or anatomopathologic variables in the 
multivariate analysis. 
DISCUSSION
The selection of studies was carried out by publications 
on the participation of these SNPs in CRC[25­30]. Due to 
involvement of angiogenesis in neoplasms, VEGF-A 
may influence the biology and the phenotype of the 
CRC[33­36]. The results regarding the association of 
polymorphisms of VEGF-A with CRC prognosis are 
controversial[13,29,36­38].
In the present analysis, we examined whether two 
common VEGF-A ­1498C>T and VEGF-A ­634G>C 
polymorphisms were related to prognoses and clinico­
pathologic features of CRC patients whose tumors had 
been surgically resected with curative intent. 
We used blood samples of patients with colorectal 
carcinoma because the majority of polymorphism 
analyses have been carried out on germline DNA 
extracted from peripheral blood as it is easily obtained 
and generates large amounts of high quality DNA. 
Fixation in paraffin­embedded tissue can cause cross­
linking and damage of DNA isolated damaging the 
amplification reaction and primer pattern recognition, 
besides mutation artifacts, e.g., artificial C­T or G­A 
transitions[39]. 
The results of the present study did not support 
an association of the VEGF-A ­1498C>T and VEGF-A 
­634G>C polymorphisms with tumor size, histological 
grading, tumor stage, lymph node metastasis and age 
at diagnosis in CRC cases. In the same way, Hofmann 
et al[28] and Dassoulas et al[36] found no correlation 
between the VEGF-A ­634G>C and VEGF-A ­1498C>T 
polymorphisms and the tumor characteristics. On the 
other hand, Chae et al[40] showed that the T allele was 
related to the advanced stage of CRC. 
Kim et al[29] reported that ­634GC and ­634CC 
genotypes were associated with a favorable prognosis 
compared to ­634GG genotype VEGF-A polymorphism 
  Stage (n) C/C 
n  (%)
G/C 
n  (%)
G/G 
n  (%)
  I + II (55) 10 (18.2) 22 (40.0) 23 (4I.8)
  III + IV (63) 16 (25.4) 20 (31.7) 27 (42.9)
  Total 26 (22.0)    42 (35.6%) 50 (42.4)
  P - 0.27 0.53
  OR (95%CI) 1 0.56 (0.21-1.53) 0.73 (0.27-1.92)
Table 2  TNM staging of colorectal tumors and their 
respective polymorphisms of vascular endothelial growth 
factor -634G>C gene (n  = 118)
Cox multiple regression test. OR: Odds ratio.
  Stage (n) C/C n  (%) G/C n  (%) G/G n  (%)
  I + II (61) 20 (32.8)   9 (14.8) 32 (52.5)
  III + IV (68) 24 (35.3) 18 (26.5) 26 (38.2)
  Total 26 (22.0) 42 (35.6) 50 (42.4)
  P - 0.31 0.33
  OR (95%CI) 1 1.66 (0.61-4.51) 0.67 (0.30-1.48)
Table 3  TNM staging of colorectal tumors and their 
respective polymorphisms of vascular endothelial growth 
factor -1498C>T gene (n  = 129)
Cox multiple regression test. OR: Odds ratio.
Liver 
metastasis
Genotype TT
n  (%)
Genotype CC
n (%)
Genotype CT 
n  (%)
Yes (25)   7 (28.0) 10 (40.0)   8 (32.0)
No (104) 37 (35.6) 17 (16.3) 50 (48.1)
  P 0.34 0.048 0.765
  OR (95%CI) 1 0.32 (0.10-0.98)1 1.18 (0.39-3.55)
Table 4  Univariate analysis of vascular endothelial growth 
factor A -1498C>T genetic polymorphism and the presence 
of liver metastasis in patients with resected colorectal 
carcinoma (n  = 129)
1Significant. OR: Odds ratio.
  Polymorphism Genotype n  (%) 5-yr survival (%) P
  VEGF-A -1498C>T 
  (n = 129)
CC 27 (20.9) 46.4 0.0321
CT 58 (44.9) 61.7
TT 44 (34.1) 67.1
Table 5  Univariate analysis of vascular endothelial growth 
factor A -1498C>T genetic polymorphism and 5-year 
survival in patients with resected colorectal carcinoma (n  = 
129)
1Significant Mantel-Cox log-rank test.
  Variables Category HR (95%CI) P
  VEGF-A -1498C>T TT 1 (reference) -
CT 2.79 (1.01- 7.66) 0.0471
CC 4.67 (1.51-14.43) 0.0071
  VEGF-A -634C>G GG 1 (reference) -
CG 1.44 (0.58-3.55) 0.433
CC 3.76 (1.29-10.93)  0.0151
Table 6  Multivariate analysis of vascular endothelial growth 
factor A -1498C>T genetic polymorphism (n  = 129) 
and vascular endothelial growth factor A -634C>G (n  = 
118) genotypes and 5-year survival in patients with resected 
colorectal carcinoma
1Significant Cox multiple regression test.
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in CRC patients. Particularly, these authors reported 
that ­634G>C VEGF-A polymorphism is an independent 
prognostic factor for CRC. Watson et al[24] observed that 
there is a significant correlation between production of 
VEGF­A protein from peripheral blood mononuclear cells 
and VEGF ­634G­A>C polymorphism. These authors 
also reported the decreased production of VEGF­A 
protein in patients with homozygotes CC VEGF-A gene 
and increased production of VEGF­A protein in homozy­
gotes GG VEGF-A genes. In the present series, the 
CC genotype of VEGF-A ­634C>G polymorphism was 
significantly related to survival in patients with resected 
colorectal carcinoma. In accordance with Kim et al[29], 
our results pointed out that 634C>C polymorphism was 
an independent prognostic factor and it was associated 
with a worse 5­year survival rate compared to the 
VEGF-A GC genotype. Dassoulas et al[36] analyzed DNA 
extracted from paraffin­embedded tissue from 312 
Greek patients with CRC in all stages and evaluated 
the prognostic value of five VEGF-A polymorphisms, 
including the ­ 634G>C and ­ 1498C>T polymorphisms. 
They reported that ­634 CC genotype was associated 
with a poor prognosis in the Greek population, which 
agree with the results we found with Brazilian patients 
in the present series. Dassoulas et al[36] concluded that, 
in Greek patients with CRC, VEGF-A ­ 634G>C and ­ 
1498C>T, polymorphisms were independent markers 
of prognosis. Hansen et al[41] demonstrated obvious 
relationships between genetic variations in the VEGF-A 
gene and response to first-line capecitabine in patients 
with metastatic colorectal cancer, which translated to a 
significant difference in progression-free survival. 
Chae et al[40] analyzed the associations of VEGF-A 
­634G>C polymorphism in patients with CRC. These 
authors observed that there was no significant 
correlation between the genotype GC with TNM stage 
III/IV, lymph node involvement and distant metastasis 
in CRC. On the other hand, Jang et al[42] genotyped the 
VEGF-A ­634G>C polymorphism in 350 CRC cases from 
the Korean population. The results suggest that this 
genetic polymorphism variant is not a potential genetic 
marker for CRC prognosis. 
However, Hansen et al[41] reported opposite results. 
The authors studied CRC in Danish patients with 
stages II and III and found that ­634GC heterozygote 
genotype exhibited lower free disease and survival rates 
compared to the corresponding wild­type homozygote 
genotypes. This result was the opposite of what we 
found in the present study. 
Kjaer­Frifeldt et al[43] found in a multivariate analysis 
that VEGF-A ­1498C>T and VEGF-A ­634G>C poly­
morphisms were independent prognostic factors for the 
risk of death of patients by CCR, as we observed in our 
cases. 
The difference between the results of these studies 
is not sufficiently clear. The discrepancy between the 
studies of VEGF-A polymorphism and CRC prognosis 
can be attributed to the differences in disease status, 
race and size of the sample studied[29,36]. Another 
possible explanation for these results is the DNA 
sequence variations in the VEGF-A, variation in the gene 
locus, action by several other genes and environmental 
characteristics. All these variables may alter VEGF­A 
production and/or activity, thereby causing inter­
individual differences in the lymphangiogenesis and 
lymphatic tumor spread and, thus, in the development 
and progression of the tumors[29,36,39]. The differential 
role that individual polymorphisms of VEGF-A may play 
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Figure 1  The Kaplan-Meier survival curves as a function of vascular 
endothelial growth factor A-1498C>T genetic polymorphism genotypes in 
colorectal cancer patients. VEGF: Vascular endothelial growth factor.
Figure 2  The Kaplan-Meier survival curves as a function of vascular 
endothelial growth factor A -634G>C genetic polymorphism genotypes in 
colorectal cancer patients. VEGF: Vascular endothelial growth factor.
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in the biological activity of VEGF­A protein secreted by 
intratumoral variability of VEGF-A genetic expression is 
enhanced by these findings. In a large meta-analysis, 
involving 27 studies Des Guetz et al[19] demonstrated 
that VEGF-A overexpression is significantly correlated 
with poor overall survival and with an increased risk of 
relapse in CRC patients.
The differences between the results of published 
studies can be attributed to the different sources of DNA, 
the different ethnic backgrounds of the patients studied, 
the number of patients tested, the different designs 
of the studies, a lack of prospective randomized trials, 
laboratory tests, numerous genetic polymorphisms and 
errors in the interpretation of results[44­46]. 
In summary, in the univariate analysis we found 
an association between genotype CC of the VEGF-A 
­1498C>T polymorphism and the occurrence of hepatic 
metastasis of CRC. In the multivariate analysis, geno­
types CT and CC of VEGF-A ­1498C>T polymorphism 
and genotype CC of VEGF-A ­634C>G genetic poly­
morphism are independent prognostic factors for the risk 
of death in Brazilian patients with sporadic CRC. 
The study of VEGF-A polymorphisms can bring 
new impacts on pharmacogenetics as VEGF­A is an 
important target in antineoplastic therapy, and the 
results of the VEGF-A polymorphisms may enhance the 
targeted therapies. This approach will be of great help 
to physicians in terms of tailoring individual therapies 
and enhancing the quality of patients’ postoperative 
treatment. Moreover, since genetic polymorphisms 
often show a discrepancy between ethnic groups, more 
studies are also warranted to clarify the association 
between the VEGF-A polymorphisms and the CRC in 
diverse ethnic populations. 
In conclusion, our data suggested that the CT and 
CC genotypes of the VEGF-A ­1498C>T polymorphisms 
and the CC genotype of the VEGF-A ­634C>G poly­
morphisms are independent prognostic factors for the 
risk of death in Brazilian patients with sporadic colorectal 
carcinoma. 
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is a potential marker for determining the prognosis of CRC and it has also been 
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associated with a higher VEGF-A expression.
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between individuals from different ethnic groups, and there are few studies 
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The contribution of common VEGF-A genetic polymorphisms to the CRC 
prognosis remains unclear. Furthermore, studies investigating the association 
between VEGF-A genetic polymorphisms and CRC risk reporting conflicting 
results and the specific associations still remain controversial. Because VEGF-A 
is known to be a potent proangiogenic factor, the authors evaluated the potential 
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polymorphisms. VEGF-A protein is an important target in anticancer therapy and 
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